Mitochondrial basis for immune deficiency: Evidence from purine nucleoside phosphorylase-deficient mice

Journal of Experimental Medicine

Volumn 191, Issue 12, 2000, Pages 2197-2207

  Arpaia, Enrico ^a,b,d   Benveniste, Patricia ^a,b,d   Di Cristofano, Antonio ^c   Gu, Yiping ^a,b,d   Dalal, Ilan ^a,b,d   Kelly, Susan ^e   Hershfield, Michael ^e   Pandolfi, Pier Paolo ^c   Roifman, Chaim M ^a,b,d   Cohen, Amos ^a,b,d  

^a Division of Immunology and Allergy   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c Department of Obstetrics Gynecology   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Apoptosis; Immune deficiency; Mitochondria; Purine metabolism; T lymphocyte

Indexed keywords

PROTEIN BCL 2; PURINE NUCLEOSIDE PHOSPHORYLASE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; DNA REPAIR; IMMUNE DEFICIENCY; KNOCKOUT MOUSE; MITOCHONDRION; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PURINE METABOLISM; RADIOSENSITIVITY; T LYMPHOCYTE; THYMOCYTE;

ANIMALS; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CYTOTOXICITY, IMMUNOLOGIC; DEOXYGUANINE NUCLEOTIDES; MICE; MICE, KNOCKOUT; MITOCHONDRIA; PURINE-NUCLEOSIDE PHOSPHORYLASE; SEVERE COMBINED IMMUNODEFICIENCY; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; THYMUS GLAND;

EID: 0034686409     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.191.12.2197     Document Type: Article

References (62)

1. Giblett, E.R., J.E. Anderson, F. Cohen, B. Pollara, and H.J. Meuwissen. 1972. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet. 2:1067-1069.
2. Giblett, E.R., A.J. Ammann, D.W. Wara, R. Sandman, and L.K. Diamond. 1975. Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet. 1:1010-1013.
3. Cohen, A., L.J. Gudas, A.J. Ammann, G.E. Staal, and D.J. Martin. 1978. Deoxyguanosine triphosphate as a possible toxic metabolite in the immunodeficiency associated with purine nucleoside phosphorylase deficiency. J. Clin. Invest. 61:1405-1409.
4. Cohen, A., R. Hirschhorn, S.D. Horowitz, A. Rubinstein, S.H. Polmar, R. Hong, and D.J. Martin. 1978. Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc. Natl. Acad. Sci. USA. 75: 472-476.
5. Gudas, L.J., B. Ullman, A. Cohen, and D.J. Martin. 1978. Deoxyguanosine toxicity in a mouse T lymphoma relationship to purine nucleoside phosphorylase-associated immune dysfunction. Cell. 14:531-538.
6. Ullman, B., L.J. Gudas, A. Cohen, and D.J. Martin. 1978. Deoxyadenosine metabolism and cytotoxicity in cultured mouse T lymphoma cells: a model for immunodeficiency disease. Cell. 14:365-375.
7. Li, P., D. Nijhawan, I. Budihardjo, S.M. Srinivasula, M. Ahmad, E.S. Alnemri, and X. Wang. 1997. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 91:474-189.
8. Herschfield, M.S., and B.S. Mitchel. 1995. Immunodeficiency diseases caused by adenosine deaminase and purine nucleoside deficiency. In The Metabolic and Molecular Basis of Inherited Disease. C.R. Scriver, A.L. Reaudet, M.S. Sly, editors. McGraw-Hill Inc., New York. 1725-1768.
9. Snyder, F.F., J.P. Jenuth, E.R. Mably, and R.K. Mangat. 1997. Point mutations at the purine nucleoside phosphorylase locus impair thymocyte differentiation in the mouse. Proc. Natl. Acad. Sci. USA. 94:2522-2527.
10. Thomas, K.R., and M.R. Capecchi. 1987. Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell. 51:503-512.
11. Tybulewicz, V.L., C.E. Crawford, P.K. Jackson, R.T. Bronson, and R.C. Mulligan. 1991. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell. 65:1153-1163.
12. Yamada, Y., H. Goto, and N. Ogasawara. 1983. Purine nucleoside kinases in human T- and B-lymphoblasts. Biochim. Biophys. Acta. 761:34-40.
13. Cohen, A., J. Barankiewicz, H.M. Lederman, and E.W. Gelfand. 1983. Purine and pyrimidine metabolism in human T lymphocytes. Regulation of deoxyribonucleotide metabolism. J. Biol. Chem. 258:12334-12340.
14. Snyder, F.F., J.P. Jenuth, J.E. Dilay, E. Fung, T. Lightfoot, and E.R. Mably. 1994. Secondary loss of deoxyguanosine kinase activity in purine nucleoside phosphorylase deficient mice. Biochim. Biophys. Acta. 1227:33-40.
15. Trounce, I.A., Y.L. Kim, A.S. Jun, and D.C. Wallace. 1996. Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial cell lines. Methods Enzymol. 264:484-509.
16. Sherman, P.A., and J.A. Fyfe. 1989. Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers. Anal. Biochem. 180:222-226.
17. Cohen, A., D. Doyle, D.W. Martin, and A.J. Ammann, Jr. 1976. Abnormal purine metabolism and purine overproduction in a patient deficient in purine nucleoside phosphorylase. N. Engl. J. Med. 295:1449-1454.
18. Sentman, C.L., J.R. Shutter, D. Hockenbery, O. Kanagawa, and S.J. Korsmeyer. 1991. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell. 67: 879-888.
19. Ravagnan, L., I. Marzo, P. Costantini, S.A. Susin, N. Zamzami, P.X. Petit, F. Hirsch, M. Goulbern, M.F. Poupon, L. Miccoli, et al. 1999. Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore. Oncogene. 18:2537-2546.
20. + thymocytes by p56lck tyrosine kinase: basis for differential signaling by CD4 and CD8 in immature thymocytes expressing both coreceptor molecules. J. Exp. Med. 178:1701-1712.
21. Simmonds, H.A., A.R Watson, D.R. Webster, A. Sahota, and D. Perrett. 1982. GTP depletion and other erythrocyte abnormalities in inherited PNP deficiency. Biochem. Pharmacol. 31:941-946.
22. Cohen, A., J. Barankiewicz, H.M. Lederman, and E.W. Gelfand. 1984. Purine metabolism in human T lymphocytes: role of the purine nucleoside cycle. Can. J. Biochem. Cell Biol. 62:577-583.
23. Jenuth, J.P., J.E. Dilay, E. Fung, E.R. Mably, and F.F. Snyder. 1991. Absence of dGTP accumulation and compensatory loss of deoxyguanosine kinase in purine nucleoside phosphorylase deficient mice. Adv. Exp. Med. Biol. 309B: 273-277.
24. Johansson, M., and A. Karlsson. 1996. Cloning and expression of human deoxyguanosine kinase cDNA. Proc. Natl. Acad. Sci. USA. 93:7258-7262.
25. Park, I., and D.H. Ives. 1988. Properties of a highly purified mitochondrial deoxyguanosine kinase. Arch. Biochem. Biophys. 266:51-60.
26. Zhu, C., M. Johansson, J. Permert, and A. Karlsson. 1998. Phosphorylation of anticancer nucleoside analogs by human mitochondrial deoxyguanosine kinase. Biochem. Pharmacol. 56:1035-1040.
27. Johansson, M., S. Brismar, and A. Karlsson. 1997. Human deoxycytidine kinase is located in the cell nucleus. Proc. Natl. Acad. Sci. USA. 94:11941-11945.
28. Ernst, J.D., L. Yang, J.L. Rosales, and V.C. Broaddus. 1998. Preparation and characterization of an endogenously fluorescent annexin for detection of apoptotic cells. Anal. Biochem. 260:18-23.
29. Posmantur, R., K.K. Wang, R. Nath, and R.B. Gilbertsen. 1997. A purine nucleoside phosphorylase (PNP) inhibitor induces apoptosis via caspase-3-like protease activity in MOLT-4 T cells. Immunopharmacology. 37:231-244.
30. Ullman, B., L.J. Gudas, S.M. Clift, and D.J. Martin. 1979. Isolation and characterization of purine-nucleoside phosphorylase-deficient T-lymphoma cells and secondary mutants with altered ribonucleotide reductase: genetic model for immunodeficiency disease. Proc. Natl. Acad. Sci. USA. 76:1074-1078.
31. Cohen, A., and E. Thompson. 1986. DNA repair in nondividing human lymphocytes: inhibition by deoxyadenosine. Cancer Res. 46:1585-1588.
32. Martin, D.J., and E.W. Gelfand. 1981. Biochemistry of diseases of immunodevelopment. Annu. Rev. Biochem. 50:845-877.
33. Snyder, F.F., J.P. Jenuth, E.R. Mably, R.K. Mangat, and R.A. Pinto. 1998. Purine nucleoside phosphorylase deficient mice exhibit both an age dependent attrition of thymocytes and impaired thymocyte differentiation. Adv. Exp. Med. Biol. 431:515-518.
34. Sandman, R., A.J. Ammann, C. Grose, and D.W. Wara. 1977. Cellular immunodeficiency associated with nucleoside phosphorylase deficiency. Immunologic and biochemical studies. Clin. Immunol. Immunopathol. 8:247-253.
35. Stoop, J.W., B.J. Zegers, G.F. Hendrickx, H.L. van Heukelom, G.E. Staal, P.K. de Bree, S.K. Wadman, and R.E. Ballieux. 1977. Purine nucleoside phosphorylase deficiency associated with selective cellular immunodeficiency. N. Engl. J. Med. 296:651-655.
36. Markert, M.L. 1991. Purine nucleoside phosphorylase deficiency. Immunodefic. Rev. 3:45-81.
37. Cohen, A., E. Grunebaum, E. Arpaia, and C.M. Roifman. 2000. Immunodeficiency caused by purine nucleoside phosphorylase deficiency. In Clinics of North America. C.M. Roifman, editor. W.B. Saunders Co., Philadelphia. 129-159.
38. Hershfield, M.S., S. Chaffee, J.L. Koro, A. Mary, A.A. Smith, and S.A. Short. 1991. Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with polyethylene glycol. Proc. Natl. Acad. Sci. USA. 88:7185-7189.
39. Sidi, Y., I. Gelvan, S. Brosh, J. Pinkhas, and O. Sperling. 1989. Guanine nucleotide metabolism in red blood cells: the metabolic basis for GTP depletion in HGPRT and PNP deficiency. Adv. Exp. Med. Biol. 153B:67-71.
40. Bjursell, G., and L. Skoog. 1980. Control of nucleotide pools in mammalian cells. Antibiot. Chemother. 28:78-85.
41. Reichard, P. 1985. Ribonucleotide reductase and deoxyribonucleotide pools. Basic Life Sci. 31:33-45.
42. Park, I., and D.H. Ives. 1995. Kinetic mechanism and end-product regulation of deoxyguanosine kinase from beef liver mitochondria. J. Biochem. 117:1058-1061.
43. Yamada, Y., H. Goto, and N. Ogasawara. 1983. Regulation of human placental deoxyguanosine kinase by nucleotides. FEBS Lett. 157:51-53.
44. Wang, L., U. Hellman, and S. Eriksson. 1996. Cloning and expression of human mitochondrial deoxyguanosine kinase cDNA. FEBS Lett. 390:39-43.
45. Eriksson, S., E. Arner, T. Spasokoukotskaja, L. Wang, A. Karlsson, O. Brosjo, P. Gunven, G. Julusson, and J. Liliemark.1994. Properties and levels of deoxynucleoside kinases in normal and tumor cells; implications for chemotherapy. Adv. Enzyme. Regul. 34:13-25.
46. Carson, D.A., J. Kaye, and J.E. Seegmiller. 1977. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s). Proc. Natl. Acad. Sci. USA. 74:5677-5681.
47. Johansson, M., S. Bajalica-Lagercrantz, J. Lagercrantz, and A. Karlsson. 1996. Localization of the human deoxyguanosine kinase gene (DGUOK) to chromosome 2p13. Genomics. 38: 450-451.
48. Zhu, C., M. Johansson, J. Permert, and A. Karlsson. 1998. Enhanced cytotoxicity of nucleoside analogs by overexpression of mitochondrial deoxyguanosine kinase in cancer cell lines. J. Biol. Chem. 273:14707-14711.
49. Nishino, I., A. Spinazzola, and M. Hirano. 1999. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science. 283:689-692.
50. Sakiyama, T. 1996. [Purine nucleoside phosphorylase (PNP) deficiency]. Nippon Rinsho. 54:3328-3332.
51. Simmonds, H.A., L.D. Fairbanks, G.S. Morris, G. Morgan, A.R. Watson, P. Timms, and B. Singh. 1987. Central nervous system dysfunction and erythrocyte guanosine triphosphate depletion in purine nucleoside phosphorylase deficiency. Arch. Dis. Child. 62:385-391.
52. Tam, D.J., and R.T. Leshner. 1995. Stroke in purine nucleoside phosphorylase deficiency. Pediatr. Neurol. 12:146-148.
53. Cohen, A., J.W. Lee, H.M. Dosch, and E.W. Gelfand. 1980. The expression of deoxyguanosine toxicity in T lymphocytes at different stages of maturation. J. Immunol. 125:1578-1582.
54. Carson, D.A., D.B. Wasson, E. Lakow, and N. Kamatani. 1982. Possible metabolic basis for the different immunodeficient states associated with genetic deficiencies of adenosine deaminase and purine nucleoside phosphorylase. Proc. Natl. Acad. Sci. USA. 79:3848-3852.
55. Hildeman, D.A., T. Mitchell, T.K. Teague, P. Henson, B.J. Day, J. Kappler, and P.C. Marrack. 1999. Reactive oxygen species regulate activation-induced T cell apoptosis. Immunity. 10:735-744.
56. Marchetti, P., T Hirsch, N. Zamzami, M. Castedo, D. Decaudin, S.A. Susin, B. Masse, and G. Kroemer. 1996. Mitochondrial permeability transition triggers lymphocyte apoptosis. J. Immunol. 157:4830-4836.
57. Croteau, D.L., and V.A. Bohr. 1997. Repair of oxidative damage to nuclear and mitochondrial DNA in mammalian cells. J. Biol. Chem. 272:25409-25412.
58. Canman, C.E., and D.S. Lim. 1998. The role of ATM in DNA damage responses and cancer. Oncogene. 17:3301-3308.
59. Karlseder, J., D. Broccoli, Y. Dai, S. Hardy, and T. de Lange. 1999. p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science. 283:1321-1325.
60. Benveniste, P., and A. Cohen. 1995. p53 expression is required for thymocyte apoptosis induced by adenosine deaminase deficiency. Proc. Natl. Acad. Sci. USA. 92:8373-8377.
61. Wang, L., P.B. Munch, S.A. Herrstrom, U. Hellman, T. Bergman, H. Jornvall, and S. Eriksson. 1999. Human thymidine kinase 2: molecular cloning and characterisation of the enzyme activity with antiviral and cytostatic nucleoside substrates. FEBS Lett. 443:170-174.
62. Young, P., J.M. Leeds, M.B. Slabaugh, and C.K. Mathews. 1994. Ribonucleotide reductase: evidence for specific association with HeLa cell mitochondria. Biochem. Biophys. Res. Commun. 203:46-52.